Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “LTD.”

1,301 pharma patents match "LTD." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,301
Index total 30,257
Page 22 / 55

Quick answer

This filtered view shows 1,301 pharmaceutical patents matching "LTD." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,301 results for “LTD.” · 30,257 patents in full index Clear search

  1. US 9675588

    Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms

    RedHill Biopharma Ltd. · Granted Jun 13, 2017 · Expires Jun 8, 2037

    granted
  2. US 9670194

    Substituted aminopyrimidine compounds and methods of use

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Jun 6, 2017 · Expires Jun 1, 2037

    granted
  3. US 9662349

    Dietary composition having mixed polysaccharides derived from lucid ganoderma, lycium barbarum and polygonatum sibiricum and method of its preparation

    INFINITUS (CHINA) COMPANY LTD. · Granted May 30, 2017 · Expires May 25, 2037

    granted
  4. US 9663498

    Aromatic heterocyclic compounds and their application in pharmaceuticals

    SUNSHINE LAKE PHARMA CO., LTD. · Granted May 30, 2017 · Expires May 25, 2037

    granted
  5. US 9662322

    Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted May 30, 2017 · Expires May 25, 2037

    granted
  6. US 9657007

    Substituted aminopyrimidine compounds and methods of use

    SUNSHINE LAKE PHARMA CO., LTD. · Granted May 23, 2017 · Expires May 18, 2037

    granted
  7. US 9655938

    Compositions of polymeric myrcene

    REGENERA PHARMA LTD. · Granted May 23, 2017 · Expires May 18, 2037

    granted
  8. US 9636305

    Antiemetic extended release solid dosage forms

    RedHill Biopharma Ltd. · Granted May 2, 2017 · Expires Apr 27, 2037

    granted
  9. US 9637519

    Peptide for inducing mast cell-specific apoptosis and use thereof

    CAREGEN CO., LTD. · Granted May 2, 2017 · Expires Apr 27, 2037

    granted
  10. US 9629385

    Dietary composition containing cistanche deserticola polysaccharide with inhibitory effects on colon cancer

    INFINITUS (CHINA) COMPANY LTD. · Granted Apr 25, 2017 · Expires Apr 20, 2037

    granted
  11. US 9625473

    Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Apr 18, 2017 · Expires Apr 13, 2037

    granted
  12. US 9624259

    Compositions and methods for scaffold formation

    REGENTIS BIOMATERIALS LTD. · Granted Apr 18, 2017 · Expires Apr 13, 2037

    granted
  13. US 9617596

    Biomarkers predictive for clinical response for glatiramer acetate

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Apr 11, 2017 · Expires Apr 6, 2037

    granted
  14. US 9609883

    Method for producing wheat glutamine peptide

    CHINA NATIONAL RESEARCH INSTITUTE OF FOOD & FERMENTATION INDUSTRIES CO., LTD. · Granted Apr 4, 2017 · Expires Mar 30, 2037

    granted
  15. US 9610331

    Methods for hematopoietic precursor mobilization

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Apr 4, 2017 · Expires Mar 30, 2037

    granted
  16. US 9603907

    Dry powder formulations of dNase I

    Protalix Ltd. · Granted Mar 28, 2017 · Expires Mar 23, 2037

    granted
  17. US 9603806

    Pharmaceutical compositions for the treatment of Helicobacter pylori

    RedHill Biopharma Ltd. · Granted Mar 28, 2017 · Expires Mar 23, 2037

    granted
  18. US 9603906

    Inhalable liquid formulations of DNase I

    Protalix Ltd. · Granted Mar 28, 2017 · Expires Mar 23, 2037

    granted
  19. US 9598401

    Substituted heteroaryl compounds and methods of use thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Mar 21, 2017 · Expires Mar 16, 2037

    granted
  20. US 9598400

    Substituted quinoline compounds and methods of use

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Mar 21, 2017 · Expires Mar 16, 2037

    granted
  21. US 9585878

    Treatment of BDNF-related disorders using laquinimod

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Mar 7, 2017 · Expires Mar 2, 2037

    granted
  22. US 9574012

    AGR2 blocking antibody and use thereof

    Sanofi (China) Investment Co., Ltd. Shanghai Branch · Granted Feb 21, 2017 · Expires Feb 16, 2037

    granted
  23. US 9573953

    Heteroaromatic compounds as PI3 kinase modulators and methods of use

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Feb 21, 2017 · Expires Feb 16, 2037

    granted
  24. US 9567300

    Hexahydropentaleno derivatives, preparation method and use in medicine thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Feb 14, 2017 · Expires Feb 9, 2037

    granted